Advertisement
YOU ARE HERE: LAT HomeCollectionsVitarine Pharmaceuticals Inc
IN THE NEWS

Vitarine Pharmaceuticals Inc

FEATURED ARTICLES
ARTICLES BY DATE
Advertisement
NEWS
August 29, 1989 | MARLENE CIMONS, Times Staff Writer
The Food and Drug Administration, escalating its campaign against generic drugs that it believes have been marketed improperly, announced Monday that it will withdraw approval of the last remaining generic equivalent of Dyazide, a leading blood pressure drug. The FDA said it could no longer be certain that Bolar Pharmaceutical's generic drug, one of the nation's best-selling generics, is precisely equivalent to Dyazide.
NEWS
September 1, 1989 | MARLENE CIMONS, Times Staff Writer
Federal officials are investigating Bolar Pharmaceutical Co. for possible fraud in connection with the approval of a generic version of the brand-name anti-depressant drug Mellaril. Knowledgeable officials said Thursday that both the Food and Drug Administration and the House Energy and Commerce oversight subcommittee are looking into charges that Bolar fraudulently submitted the brand-name drug instead of the generic version to a testing laboratory--the second such incident reported.
NEWS
September 1, 1989 | MARLENE CIMONS, Times Staff Writer
Federal officials are investigating Bolar Pharmaceutical Co. for possible fraud in connection with the approval of a generic version of the brand-name anti-depressant drug Mellaril. Knowledgeable officials said Thursday that both the Food and Drug Administration and the House Energy and Commerce oversight subcommittee are looking into charges that Bolar fraudulently submitted the brand-name drug instead of the generic version to a testing laboratory--the second such incident reported.
BUSINESS
December 18, 1992 | From Times Staff and Wire Reports
Bolar Pharmaceutical Faces Price-Fixing Charges: A federal grand jury in Baltimore has indicted Bolar Pharmaceutical Co. and its president, Lawrence Raisfeld, on charges of conspiring to fix the price of a generic high blood-pressure medicine, the Justice Department said. According to the one-count indictment, Bolar Pharmaceutical and Raisfeld conspired with Vitarine Pharmaceuticals Inc. of Springfield Gardens, N.Y.
BUSINESS
June 30, 1989 | From Reuters
A New York drug company acknowledged today that it gained federal approval to market a popular generic high blood pressure drug by submitting another firm's product for government testing. Vitarine Pharmaceuticals Inc. of Springfield Gardens, N.Y., has informed the Food and Drug Administration that it gained agency approval for a copycat version of the blood pressure drug Dyazide by putting the brand name version of the drug in its capsules and submitting these for FDA evaluation, Roger W. Jordan, Vitarine chief executive officer, told Reuters.
NEWS
August 24, 1989 | MARLENE CIMONS, Times Staff Writer
The Food and Drug Administration will take punitive action against two generic drug companies implicated in a bribery scandal and plans to inspect the plants of another 20 leading manufacturers, the agency announced Wednesday. The agency will seek to permanently remove from the market more than two dozen drugs made by Par Pharmaceuticals of Spring Valley, N.Y., and Vitarine Pharmaceuticals Inc., of Springfield, N.Y., the agency said.
NEWS
August 29, 1989 | MARLENE CIMONS, Times Staff Writer
The Food and Drug Administration, escalating its campaign against generic drugs that it believes have been marketed improperly, announced Monday that it will withdraw approval of the last remaining generic equivalent of Dyazide, a leading blood pressure drug. The FDA said it could no longer be certain that Bolar Pharmaceutical's generic drug, one of the nation's best-selling generics, is precisely equivalent to Dyazide.
Los Angeles Times Articles
|